These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 33685460)

  • 21. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
    Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.
    Chen Z; Wang X; Yan Z; Zhang M
    Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
    Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
    Front Immunol; 2021; 12():755401. PubMed ID: 34917077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
    Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
    World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma.
    Hu J; Yuan Z; Jiang Y; Mo Z
    J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
    Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
    Front Genet; 2022; 13():886983. PubMed ID: 35547260
    [No Abstract]   [Full Text] [Related]  

  • 28. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
    Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
    Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
    Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
    BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development.
    Chen Y; Jiang N; Chen M; Sui B; Liu X
    Front Cell Dev Biol; 2022; 10():1064754. PubMed ID: 36467412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.
    Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
    Front Genet; 2021; 12():701065. PubMed ID: 34527020
    [No Abstract]   [Full Text] [Related]  

  • 32. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
    Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
    Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
    Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma.
    Wu C; Duan Y; Gong S; Osterhoff G; Kallendrusch S; Schopow N
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development.
    Chen X; Zhang T; Zhai X; Wan Z; Ge M; Liu C; Tan M; Xu D
    Front Immunol; 2022; 13():1037808. PubMed ID: 36405755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development.
    Li RQ; Wang W; Yan L; Song LY; Guan X; Zhang W; Lian J
    Front Oncol; 2022; 12():973712. PubMed ID: 36226063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel mutation gene signature HAMP for cholangiocarcinoma through comprehensive TCGA and GEO data mining.
    Wang Z; Du Y
    Int Immunopharmacol; 2021 Oct; 99():108039. PubMed ID: 34426102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development.
    Wang S; Yang Y; Li L; Ma P; Jiang Y; Ge M; Yu Y; Huang H; Fang Y; Jiang N; Miao H; Guo H; Yan L; Ren Y; Sun L; Zha Y; Li N
    Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 35893817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of tumour antigens and immune subtypes in the development of an anti-cancer vaccine for endometrial carcinoma.
    Feng J; He H
    Scand J Immunol; 2023 Mar; 97(3):e13250. PubMed ID: 36575819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma.
    Zhou B; Zang R; Zhang M; Song P; Liu L; Bie F; Peng Y; Bai G; Gao S
    Int Immunopharmacol; 2022 Aug; 109():108816. PubMed ID: 35504200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.